TD Cowen analyst Bryan Bergin lowered the firm’s price target on Genpact to $40 from $44 and keeps a Market Perform rating on the shares. The firm said its 2Q print was a mixed bag with light 2Q revenue and reductions to 2023 revenue and EPS outlooks, but another quarter of strong bookings that support 2024 growth recovery optimism.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on G: